Age-Related Eye Disease Study 2 (AREDS2)
Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration
Sponsor: National Center for Complementary and Integrative Health (NCCIH)
Listed as NCT00345176, this PHASE3 trial focuses on Age-related Macular Degeneration and Cataract and remains completed. Sponsored by National Center for Complementary and Integrative Health (NCCIH), it has been updated 9 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Center for Complementary and Integrative Health (NCCIH)
- National Eye Institute (NEI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Office of Dietary Supplements (ODS)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arlington, United States, Asheville, United States, Atlanta, United States, Baltimore, United States, Bethesda, United States, Beverly Hills, United States, Birmingham, United States, Boston, United States, Burlington, United States, Camp Hill, United States and 63 more location s